CA2341767A1 - Promotion ou inhibition d'angiogenese et de cardiovascularisation - Google Patents

Promotion ou inhibition d'angiogenese et de cardiovascularisation Download PDF

Info

Publication number
CA2341767A1
CA2341767A1 CA002341767A CA2341767A CA2341767A1 CA 2341767 A1 CA2341767 A1 CA 2341767A1 CA 002341767 A CA002341767 A CA 002341767A CA 2341767 A CA2341767 A CA 2341767A CA 2341767 A1 CA2341767 A1 CA 2341767A1
Authority
CA
Canada
Prior art keywords
polypeptide
pro230
pro216
pro302
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341767A
Other languages
English (en)
Inventor
Sherman Fong
Mary E. Gerritsen
Audrey Goddard
Austin L. Gurney
Kenneth J. Hillan
P. Mickey Williams
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/019177 external-priority patent/WO1999014234A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2341767A1 publication Critical patent/CA2341767A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne des compositions et des procédés de stimulation ou d'inhibition d'angiogénèse et/ou de cardiovascularisation chez des mammifères, y compris chez des humains. Des compositions pharmaceutiques sont basées sur des polypeptides ou des antagonistes de l'invention identifiés pour une ou plusieurs de ces utilisations. Il est possible de diagnostiquer, de prévenir ou de soigner à l'aide des compositions de l'invention des troubles comprenant des traumatismes tels que des plaies, de nombreux cancers, et des troubles vasculaires y compris l'athérosclérose et l'hypertrophie cardiaque.
CA002341767A 1998-09-14 1999-09-13 Promotion ou inhibition d'angiogenese et de cardiovascularisation Abandoned CA2341767A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10026298P 1998-09-14 1998-09-14
USPCT/US98/19177 1998-09-14
PCT/US1998/019177 WO1999014234A2 (fr) 1997-09-17 1998-09-14 Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
US60/100,262 1998-09-14
PCT/US1999/020944 WO2000015792A2 (fr) 1998-09-14 1999-09-13 Promotion ou inhibition d'angiogenese et de cardiovascularisation

Publications (1)

Publication Number Publication Date
CA2341767A1 true CA2341767A1 (fr) 2000-03-23

Family

ID=22278870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341767A Abandoned CA2341767A1 (fr) 1998-09-14 1999-09-13 Promotion ou inhibition d'angiogenese et de cardiovascularisation

Country Status (9)

Country Link
EP (1) EP1112361A2 (fr)
JP (1) JP2003524599A (fr)
KR (1) KR20010085792A (fr)
AU (1) AU5920099A (fr)
CA (1) CA2341767A1 (fr)
IL (1) IL141537A0 (fr)
MX (1) MXPA01002546A (fr)
WO (1) WO2000015792A2 (fr)
ZA (1) ZA200101453B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134814A1 (en) * 2001-11-13 2003-07-17 Millennium Pharmaceuticals, Inc. Method of using 18080, a human serine carboxypeptidase family member
CA2416538A1 (fr) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
AU2001275707A1 (en) * 2000-07-26 2002-02-05 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
EP1436390A4 (fr) * 2001-02-22 2005-07-20 Univ Rochester Proteines inductibles par un retinoide de cellules de muscles lisses vasculaires et utilisations associees
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
WO1995029242A1 (fr) * 1994-04-26 1995-11-02 The Children's Medical Center Corporation Angiostatine et procede d'utilisation de ladite substance pour inhiber l'angiogenese
WO1999014327A2 (fr) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer
AU6118498A (en) * 1997-02-28 1998-09-18 Institute Of Cytosignal Research, Inc. Intracellular signal transmission inhibitor
WO1999035158A1 (fr) * 1998-01-07 1999-07-15 Human Genome Sciences, Inc. 36 proteines humaines secretees
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
WO1999043831A1 (fr) * 1998-02-25 1999-09-02 Smithkline Beecham Plc Cprot03, cysteine protease humaine

Also Published As

Publication number Publication date
AU5920099A (en) 2000-04-03
MXPA01002546A (es) 2004-06-11
KR20010085792A (ko) 2001-09-07
WO2000015792A2 (fr) 2000-03-23
WO2000015792A3 (fr) 2000-09-21
IL141537A0 (en) 2002-03-10
ZA200101453B (en) 2002-02-21
JP2003524599A (ja) 2003-08-19
EP1112361A2 (fr) 2001-07-04

Similar Documents

Publication Publication Date Title
CA2322792C (fr) Polypeptides homologues de vegf et bmp1
EP1135485B1 (fr) Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
AU768694B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A2 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
JP2012246296A (ja) 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
JP2003531811A5 (fr)
JP2009019032A (ja) 血管形成及び心臓血管新生の促進又は阻害
WO1999014234A2 (fr) Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
CA2341767A1 (fr) Promotion ou inhibition d'angiogenese et de cardiovascularisation
EP2042597B1 (fr) Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
AU2003204852B2 (en) Polypeptides homologous to VEGF and BMP1
EP1734051A2 (fr) Composition et procédés de diagnostic de tumeurs
NZ540754A (en) Promotion or inhibition of angiogenesis and cardiovascularization

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued